U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07123350) titled 'Evaluating the Shift From Intravenous to Subcutaneous Vedolizumab for Inflammatory Bowel Disease' on Aug. 07.
Brief Summary: The goal of this retrospective study is to learn about dosing patterns in patients starting subcutaneous vedolizumab administration and patient outcomes after starting subcutaneous administration.
Patients with IBD who are starting subcutaneous vedolizumab administration between September 1, 2023, and December 31, 2024, as part of normal patient care, will be retrospectively reviewed and analyzed.
Study Start Date: Oct. 01
Study Type: OBSERVATIONAL
Condition:
Inflammatory Bowel Disease (IBD)
Crohn&Amp;#39...